|
Jul 9
|
AstraZeneca PLC (AZN): Is This FTSE Dividend Stock a Good Buy Right Now?
|
|
Jun 21
|
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
|
|
Jun 21
|
AstraZeneca’s Truqap and Faslodex combo receives approval in EU
|
|
Jun 20
|
Why Wall Street Is Chasing Ozempic Wannabes
|
|
Jun 20
|
AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer
|
|
Jun 19
|
AstraZeneca’s Truqap flops in Phase III triple negative breast cancer trial
|
|
Jun 19
|
Admiral Group And Two Other UK Exchange Stocks Estimated As Undervalued For Investment Consideration
|
|
Jun 18
|
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
|
|
Jun 18
|
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
|
|
Jun 18
|
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
|
|
Jun 18
|
One AstraZeneca Insider Raised Stake By 50% In Previous Year
|
|
Jun 16
|
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
|
|
Jun 14
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jun 14
|
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
|
|
Jun 13
|
AstraZeneca CFO: 'We've come a long way in our oncology portfolio'
|
|
Jun 13
|
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
|
|
Jun 13
|
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
|
|
Jun 13
|
FDA approves AstraZeneca’s Farxiga for paediatric T2D patients
|
|
Jun 12
|
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
|
|
Jun 12
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|